Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.72 |
| ▸ | CA1 | P00915 | 1/20 | 0.72 |
| ▸ | CA2 | P00918 | 1/20 | 0.72 |
| ▸ | CA3 | P07451 | 1/20 | 0.72 |
| ▸ | CA4 | P22748 | 1/20 | 0.72 |
| ▸ | CA6 | P23280 | 1/20 | 0.72 |
| ▸ | CA5A | P35218 | 1/20 | 0.72 |
| ▸ | CA7 | P43166 | 1/20 | 0.72 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.72 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.72 |
| ▸ | CA9 | Q16790 | 1/20 | 0.72 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.72 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.72 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.72 |
| ▸ | ANPEP | P15144 | 1/20 | 0.53 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | FNTA | P49354 | 1/20 | 0.47 |
| ▸ | FNTB | P49356 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464926 | 1.00 | CA12 (0.72) | CA12CA1CA2CA3CA4 | |
| SCHEMBL12188567 | 0.94 | CA12 (0.68) | CA12CA1CA2CA3CA4 | |
| SCHEMBL12168507 | 0.92 | CA12 (0.68) | CA12CA1CA2CA3CA4 | |
| SCHEMBL994350 | 0.92 | CA12 (0.68) | CA12CA1CA2CA3CA4 | |
| SCHEMBL991043 | 0.91 | CA12 (0.64) | CA12CA1CA2CA3CA4 | |
| SCHEMBL991042 | 0.91 | CA12 (0.64) | CA12CA1CA2CA3CA4 | |
| SCHEMBL12188566 | 0.90 | CA12 (0.65) | CA12CA1CA2CA3CA4 | |
| SCHEMBL993251 | 0.90 | SCN9A (0.65) | CA12CA1CA2CA3CA4 | |
| SCHEMBL2849775 | 0.89 | CA12 (0.57) | CA12CA1CA2CA3CA4 | |
| SCHEMBL992899 | 0.88 | CA12 (0.66) | CA12CA1CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519183-B2 | Uses for amino acid anticonvulsants | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20100273716-A1 | NEW USES FOR AMINO ACID ANTICONVULSANTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-7772427-B2 | Uses for amino acid anticonvulsants | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20070142297-A1 | New uses for amino acid anticonvulsants | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-7186859-B2 | Uses for amino acid anticonvulsants | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-RE38551-E1 | ADMINISTERING N-BENZYL-2- ACETAMIDO PROPIONAMIDE DERIVATIVES IN THE R CONFIGURATION, SUCH AS LACOSAMIDE | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2004-07-06 | — | — | US | disclosed |
| EP-1038522-B1 | Anticonvulsant enantiomeric amino acid derivatives | RES CORP TECHNOLOGIES INC (US) | 2004-06-02 | — | — | EP | disclosed |
| EP-0888289-B1 | ANTICONVULSANT ENANTIOMERIC AMINO ACID DERIVATIVES | RES CORP TECHNOLOGIES INC (US) | 2001-06-13 | — | — | EP | disclosed |
| EP-1038522-A2 | Anticonvulsant enantiomeric amino acid derivatives | Research Corporation Technologies, Inc (US) | 2000-09-27 | — | — | EP | disclosed |
| EP-0888289-A1 | ANTICONVULSANT ENANTIOMERIC AMINO ACID DERIVATIVES | Research Corporation Technologies, Inc (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5773475-A | DIPEPTIDES FOR CENTRAL NERVOUS SYSTEM DISORDERS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-06-30 | — | — | US | disclosed |
| WO-1997033861-A1 | ANTICONVULSANT ENANTIOMERIC AMINO ACID DERIVATIVES | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1997-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142297-A1 | New uses for amino acid anticonvulsants | SLC1A2, SLC1A1, SLC1A3 | CA12 886/4885CA1 832/4885CA2 383/4885 |
| US-20100273716-A1 | NEW USES FOR AMINO ACID ANTICONVULSANTS | SLC1A2, SLC1A1, SLC1A3 | CA12 886/4885CA1 832/4885CA2 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.